Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE

158.000
+9.0006.04%
Volume:7.36M
Turnover:1.16B
Market Cap:221.36B
PE:-43.24
High:160.500
Open:151.800
Low:151.000
Close:149.000
Loading ...

BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation

Reuters
·
Yesterday

Beigene Says Pharmacyclics Litigation Is Not Having Adverse Effect on Development, Sales of Brukinsa in U.S.

THOMSON REUTERS
·
Yesterday

BeiGene Price Target Maintained With a $312.00/Share by RBC Capital

Dow Jones
·
28 Apr

BeiGene Is Maintained at Overweight by JP Morgan

Dow Jones
·
22 Apr

BeiGene Price Target Maintained With a $348.00/Share by Guggenheim

Dow Jones
·
10 Apr

Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide

MT Newswires Live
·
09 Apr

Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs

MT Newswires Live
·
09 Apr

BeiGene Initiated at Outperform by RBC Capital

Dow Jones
·
07 Apr

RBC Initiates BeiGene at Outperform With $312 Price Target

MT Newswires Live
·
07 Apr

BeiGene to Discontinue Potential Lung Cancer Treatment Study

MT Newswires Live
·
03 Apr

BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate

Dow Jones
·
03 Apr

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

MT Newswires Live
·
31 Mar

BeiGene Net Loss Narrows 27% in 2024

MT Newswires Live
·
28 Mar

BeiGene Shareholder Hillhouse Pares Stake in Cancer Drug Company

MT Newswires Live
·
10 Mar

BeiGene Commences New Offering Period for Employee Share Purchase Plan

MT Newswires Live
·
07 Mar

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
05 Mar

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

MT Newswires Live
·
04 Mar

BofA Securities Upgrades BeiGene to Buy, Price Target is $320

MT Newswires Live
·
03 Mar

Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating

MT Newswires Live
·
03 Mar

BeiGene's Q4'24 Loss Narrows

MT Newswires Live
·
03 Mar